Area of research
Hematology · Molecular Biology
Research interest
Research interests include Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Cancer Treatment and Pharmacology, and Chronic Lymphocytic Leukemia Research.
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes
Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial
<i>In</i>-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.
Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry.
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma.
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect<sup>®</sup> MM Registry.
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study.
Development of a prognostic model for overall survival in multiple myeloma using the Connect<sup>®</sup> MM Patient Registry.
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma
Safety and efficacy of biosimilars in oncology
Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens
A Phase III Study Of Enzastaurin In Patients With High-Risk Diffuse Large B Cell Lymphoma Following Response To Primary Treatment: The Prelude Trial
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma